Occupational exposure to lead: Effects on renal function  by Hong, Changgi D. et al.
Kidney International, Vol. 18 (1980), pp. 489-494
Occupational exposure to lead: Effects on renal function
CHANGGI D, HONG, IRWIN B. HANENSON, SIDNEY LERNER, PAUL B. HAMMOND,
AMADEO J. PESCE, and VICTOR E. POLLAK
Departments of Medicine, Pathology, and Environmental Health, University of Cincinnati Medical Center, Cincinnati,
Ohio
Occupational exposure to lead: Etlects on renal function. Al-
though nephrotoxicity is common following exposure to lead, the
dose-response relationship in adults with occupational exposure
is not well understood because information is lacking on early
nephrotoxic effects. By the time serum urea nitrogen and creati-
nine levels are elevated, renal damage may be advanced and not
fully reversible. Detailed investigations of renal glomerular and
tubular function were performed in six adults with occupational
exposure to lead, in all patients, the serum creatinine and urea
nitrogen concentrations were within the normal range. GFR was
decreased in all but two. Glucose reabsorptive capacity (Tm)
was decreased in all, and this decrease was disproportionately
greater than expected from the reduced GFR in all but one. Nor-
mal values for renal plasma flow (RPF) were observed in four of
the six, and for p-aminohippurate (PAH) secretory capacity(TmPAP) in all but one. Bicarbonate reabsorptive capacity
(Tmo3) and urinary excretion of f32-microglobulin were normal
in all. Routine clinical laboratory tests are insensitive for the de-
tection of early renal effects of heavy metal exposure. Measure-
ment of renal tubular reabsorptive capacity for glucose appears
to be a sensitive method for the early detection of renal effect of
lead.
Professionnellement exposés au p10mb: Effets sur Ia fonction
rénale. Bien que Ia néphrotoxicité l'exposition au p10mb soit fré-
quente Ia relation dose-réponse chez les adultes profes-
sionnellement exposés n'est pas clairement comprise car on
manque d'information au sujet des effets néphrotoxiques pré-
coces. Au stade oü les concentrations d'azote uréique et de
créatinine sont étevées les lesions rénales peuvent étre avancées
et incomplétement réversibles. Des etudes détaillées des fon-
ctions glomérulaire et tubulaire ont été réalisées chez dix adultes
professionnellement exposés au plomb. Chez tous Ia créatinine
et l'azote uréique plasmatiques étaient dans lintervalle des Va-
leurs normales. La filtration glomérulaire (GFR) était diminuée
chez quatre d'entre eux. La capacité de reabsorption du glucose
(Tm) était diminuée chez tous, et cette diminution était propor-
tionnellement plus importante que ne l'aurait voulu Ia reduction
de GFR chez tolls les sujets sauf un. Des valeurs normales du
debit plasmatique renal (RPF) ont été observées chez quatre des
six sujets et des valeurs normales de Ia capacité de sécrétion de
PAH (TmAH) chez tolls sauf un. La capacité de reabsorption des
bicarbonates (TmHCO3) et l'excrétion urinaire de /32-micro-
globuline était normales chez tous. Les épreuves fonctionnelles
usuelles sont inefficaces pour Ia detection des effets rénaux
précoces de I'exposition aux métaux lourds. La mesure de Ia
capacité rénale de reabsorption du glucose paraIt Ctre Ia méth-
ode Ia plus sensible pour la detection précoce des effets du
plomb.
Nephrotoxicity is a common complication follow-
ing exposure to heavy metals such as lead, mer-
489
dry, and cadmium. Whereas there is evidence of a
direct correlation of the blood lead level (Bpb)
(which is considered the best practical biologic in-
dex of the body burden [1]) and impairment of
erythropoiesis [2-7], a comparable relationship with
renal injury has not been clearly defined [1].
Excessive lead exposure has been observed to re-
suit in two distinct forms of renal toxicity in chil-
dren and adults. One is the proximal renal tubular
damage manifested functionally by one or more ele-
ments of the Fanconi syndrome, and morphologi-
cally by epithelial degenerative changes. This toxic
effect on the proximal renal tubules is mainly ob-
served in children and is generally reversible [8, 9].
The other is renal failure with a reduced glomerular
filtration and interstitial fibrosis of the kidney ac-
companied by severe vascular alterations. This
form of renal disease has been reported in adults
following lead exposure and is frequently associat-
ed with gout and hypertension [10]. It may also oc-
cur in adults subsequent to childhood lead exposure
[11]. In studies of GFR in adults with occupational
exposure to lead, varying degrees of functional ab-
normalities were observed even in the asymptomat-
ic group [12—15]. In adults, the few studies of renal
tubular function following chronic occupational
lead exposure have been limited to assessment of
tubular secretory capacity of p-aminohippurate
(TmPAH) [14, 15] and of urinary excretion of amino
acids [16, 17].
In this paper, renal function, both glomerular and
tubular, was studied in six adults who had occupa-
tional exposure to lead to determine whether any
specific functional abnormalities occur prior to the
development of azotemia.
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Methods
Patients studied. The subjects were referred to
the Department of Environmental Health for medi-
cal evaluation following exposure to lead. After
documentation of such exposure by abnormally
high blood and urinary concentrations of lead, or
both, an informed consent to participate in a study
of renal function was obtained. Six male patients
qualified and were studied between April 1976 and
August 1979. Pertinent data related to lead ex-
posure are presented in Tables 1 and 2.
Briefcase histories. Patients 1, 2, and 3 worked for a construc-
tion firm and were involved in removing lead paint from an old
steel bridge with oxygen-acetylene torches. No protective mea-
sures were used against inhalation or ingestion of the dust or
fumes. Two to four weeks after beginning the job, all three devel-
oped nausea and vomiting associated with abdominal cramps.
The physical examination was entirely negative. One patient had
anemia. None had a known history of past exposure to lead.
Patients 4, 5, and 6 worked for a plant manufacturing brass
(alloy of copper, tin, and lead) bearings. Patients 4 and 6 were
exposed to fumes of molten brass for 18 and 11/2 years, respec-
tively. Patient 5 had no direct exposure to lead. He worked as a
forklift operator or shipping clerk for 22 years.
The blood lead level of patient 4 was high on a number of occa-
sions for at least 5 years prior to this investigation. He was then
removed from the high lead exposure area temporarily. He was
asymptomatic. The physical examination was negative except
for a blood pressure of 180/100 mm Hg.
Periodic monitoring for the last 7 years in patient 5 showed
blood lead concentrations ranging from 29 to 52 sgIdl with an
average of 39 g/dl. Hypertension was noted 2 years prior to this
admission and was treated with antihypertensive drugs inter-
mittently. He was asymptomatic. The only abnormality on phys-
ical examination was a blood pressure of 170/110 mm Hg with
retinal arteriolar narrowing and arteriovenous nicking.
Patient 6 had no previous exposure to lead. Blood lead was 82
and 75 gIdl at 7 and 10 months after beginning the job. His only
complaints were easy fatigability and impaired memory for the
past year. These symptoms improved following his transfer to
another job. Physical examination was negative.
Analytical methods. The venous blood samples
were collected in metal-free heparinized tubes.
Urine samples were collected in acid-rinsed plastic
jars. Lead concentration was determined by atomic
absorption spectrophotometry [18] at the Kettering
Laboratory, Cincinnati, Ohio.
The complete blood count and serum chemistry
were performed by the Coulter Counter and Techni-
con Auto-Analyzer, respectively. /32-microglobulin
in the urine was measured by radioimmunoassay
with the Phadebas f3-micro test (Pharmacia Diag-
nostics, Sweden) [19]. The total urinary protein was
measured by trichloroacetic acid precipitation and
turbidometry [20].
Clearance techniques. Measurements of renal
clearances were done by the standard technique
Table 1. Exposure history and blood lead concentration
Period of
Duration withdrawal
Age of exposure before study Blood leada
Patient yr Mode of exposure months months g/dl
34 Burning of old paint with acetylene torch 3 1 77
2 28 Burning of old paint with acetylene torch 3 1 110
3 22 Burning of old paint with acetylene torch 3 1 67
4 54 Fumesofmoltenbrass 216 2 59
5 46 Shipping clerk in brass bearing plant 264 2 34
6 26 Fumes of molten brass 17 6 63
a The normal in this laboratory is less than 40 g/dl.
Table 2. Routine laboratory dataa
11gb Hct SUN Scr Uric acid Sp1
Patient g/dl % mg/dl mg/dl mg/dl mg/dl
Blood
glucose
mg/dl Protein
Urinalysisb
Glucose
1 11.0 34 16 1.1 7.0 2.9 95 — —
2 15.3 45 12 1.1 7.4 2.9 75 — —
3 15.3 46 11 1.1 3,2 3.8 84 — —
4 12.7 39 17 1.3 7.2 3.8 107 + —
5 16.1 47 13 1.0 7.1 3.0 93 — —
6 13.0 41 16 1.2 7.5 3.5 91 — —
a Abbreviations used are Hgb, hemoglobin; Hct, hematocnt; SUN, serum urea nitrogen; Scr, serum creatinine; S, serum inorganic
phosphate.
By dipstick
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[21]. Patients drank two glasses of water after an
overnight fast, and then one glass every 30 mm dur-
ing the study to insure adequate urine flow (greater
than 5 mi/mm). All studies were conducted in a fast-
ing state with patients in the supine or semi-Fowler
position. A soft-tipped indwelling urethral catheter
was inserted for timed urine collections. A blood
sample was obtained to measure the inulin blank,
and then priming doses of inulin (50 mg/kg of body
wt) and PAH (8 mg/kg) were given i.v. This was
followed by a sustaining infusion of normal saline
solution at a rate of 1.15 to 2.30 ml!min, containing
inulin and PAH in amounts calculated to maintain a
constant plasma concentration after an equilibra-
tion period of 45 mm. For measurement of tubular
maxima, priming doses of PAH (160 mg/kg of body
wt), bicarbonate (150 mmoles of sodium bicarbo-
nate in 150 ml H20), and glucose (150 ml of 50%
dextrose solution) were given i.v. The maximum
reabsorptive capacities for PAH (TmPAH), bicarbo-
nate (TmHCj, and glucose (TmG) were measured
serially with equilibration periods of 30 to 45 mm
intervening. Plasma PAH concentration for mea-
surement of TmPAH was maintained above 30 mg/dl,
blood glucose concentration for the measurement of
TmG above 400 mg/di, and plasma bicarbonate con-
centration for the measurement of TmHCO, above 32
mEq/liter. The bladder was irrigated with Kanamy-
cm solution at the end of the study. All clearance
periods were 20 to 30 mm, and the data are ex-
pressed as the mean of three clearance periods, ad-
justed to a standard body surface area of 1.73 m2.
Results
As shown in Table 1, the blood lead concentra-
tions were clearly elevated in all except patient 5.
His blood lead, as well as the others, may have been
higher prior to removal from exposure. Lead ex-
posure ranged from 3 months to 22 years.
Clinical laboratory studies and studies on pro-
teinuria (Tables 2 and 3). Anemia of a moderate de-
gree was seen in two patients. Serum urea nitrogen
and creatinine concentrations were normal in all.
There was a slight but definite elevation in serum
urate concentration in all but one. Patient 4 had sig-
nificant proteinuria. Urinary excretion of /32-micro-
globulin was normal in all.
Renal clearance studies (Table 3). C1, and CPAH of
the patients were compared with age-adjusted nor-
mal values [22] and percentile ranks shown. Values
below the tenth percentile were considered to be
decreased. Whereas CPAH was normal in four and
decreased in two, C1 was decreased in all but two.
TmG was markedly decreased in all but one patient,
and the decrease was disproportionately greater
than expected from the reduced C1, (Fig. 1). TmPAH
was normal in all but one patient, and two had in-
creased TmPAH relative to C1 (Fig. 2). Tm110 was
normal in all patients.
Discussion
Clinical studies of renal function in adults with
occupational lead exposure showed that there was a
correlation between the duration of exposure and
Table 3. Renal function dataa
Urinary
f32-mi-
croglob-
C(r, mi/mm C1, mi/mm
—
CPAH, mi/mm TmHCO3
mEq/
Total
urinary
ulin cx-
cretion
Centile Centile Centile TmPAH TmPAH/ Tm TmG/ - mm/IOU protein ratee
Patient Patient rank' Patient rankb Patient rankb mg/mm C1, mg/mm C1 GFR mg/day pg/day
1 109 44 64 <1 593 73 81 1.27 134 2.09 2.8 UD <15
2 114 46 74 <1 407 2 109 1.47 107 1.45 2.6 UD 54
3 119 50 98 9 723 14 58 0.59 175 1.79 2.6 45 45
4 87 23 85 12 375 11 66 0.78 100 1.18 2.4 620 58
5 108 62 105 45 402 11 57 0.54 202 1.92 2.9 UD 40
6 99 12 78 <1 368 1 65 0.83 231 2.96 2.5 31 35
Normal valuesC 78±13c
0.60 to
0•89d 375±8O'
2.30 to
3.l9' 2.6 <150
30 to
370
a All the clearance and Tm (maximum reabsorptive capacity) values are adjusted to 1.73 m2 body surface area except TmHCO3. UD
means undetectable (<0.2 mg/dl).
b Percentile in the age-adjusted norm [22, 28]
Mean SD [23, 24]
d (Mean—SD) — (mean+SD) [23, 241
Geometric mean of two determinations
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20 40 60 80 100
C, rnl/min/1.73 m2
Fig. 1. Co,nparison of C1 and TmG of the patients. Statistical
data (mean 2 so) are adopted from Ref. 23. Numbers refer to
individual subjects.
20 40 60 80 100
C1,,, ml/min/1.73 m2
Fig. 2. Comparison of Cj,, and TmPAH of the patients. Statistical
data (mean 2 so) are adopted from Ref. 24. Numbers refer to
individual subjects.
elevation of BUN and serum creatinine concentra-
tions [12]. The BUN and serum creatinine concen-
trations observed in this group, however, overlaps
with the normal range, and these measurements,
therefore, are of limited value in determining
whether or not an individual patient has early neph-
rotoxicity. Cramer et al [13] showed that, in seven
patients with occupational lead exposure ranging
from 1 1/2 months to 20 years, C1 was slightly de-
creased in only one (whose exposure period was 10
years) and CPAH was normal in all. Wedeen et a! [14]
studied renal function in eight adults with occupa-
tional lead exposure ranging from 3 to 6 years. GFR
was significantly decreased in three patients. In one
patient, whose C1 was about one half of normal,
TmPAH was also decreased to approximately the
same degree. It was concluded that tubular dys-
function did not exceed the reduction in glomerular
filtration. In a later paper [15], Wedeen, Mallik, and
Batuman reported that 37% of patients exposed to
lead and who had an EDTA test demonstrating an
abnormally high body burden, had kidney dis-
ease." Of the group with "kidney disease," 71%
were considered to have lead nephropathy by ex-
clusion of other possible causes of reduced GFR. In
12 of their 15 patients with lead nephropathy,
TmPAH was determined, and 10 of them were within
the normal range. The "kidney disease" was de-
fined by a GFR less than 90 mllmin/1.73 m2 without
correction for age. This criterion for "kidney dis-
ease" would underestimate the true prevalence of
decreased GFR if there were many younger work-
ers whose GFR could be abnormally low for age
though greater than 90 mlIminIl .73 m2. Although
the mean extraction ratio of PAH in 10 subjects
with lead nephropathy was 0.89, which is not abnor-
mal, interpretation of CPAH and TmPAH was not at-
tempted. No other study of proximal tubular func-
tion in adults with occupational lead exposure with
normal or only slightly decreased GFR has been re-
ported.
Morphologic studies of biopsied kidneys from
lead wOrkers have shown degenerative changes of
proximal tubular epithelium, often with the charac-
teristics intranuclear inclusion bodies. These tubu-
lar alterations were seen more often with shorter
exposure with or without changes in glomerular fil-
tration [13, 14]. With prolonged exposure, glomeru-
lar sclerosis and chronic interstitial inflammation
accompanied by decreased glomerular filtration was
seen uniformly [13].
In this study, renal function, glomerular and
tubular, were studied in detail in six patients who
had work-related exposure to lead for 3 months to
22 years. All of them had high Bpb at the time of the
study except patient 5. As seen in Table 2, all six
patients had normal BUN and serum creatinine
concentrations. C,,, (Table 3), however, was de-
creased in all but two. The effective renal plasma
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flow measured by CPAH, on the other hand, was nor-
mal in four and decreased in two. This picture is
similar to that seen in workers who had "asympto-
matic" and 'subclinical" renal failure in the series
of Wedeen et a! [14, 15]. TmG was, however, signifi-
cantly decreased in all but one. TmPAH was normal
in all except one whose value was high. TmHCO was
normal in all.
Because there was a decrease in C1, it is neces-
sary to correlate the changes in tubular function
with the changes in GFR to test if there is any tubu-
lar dysfunction disproportionately greater than the
change in GFR. There are few data on simultaneous
observations of changes in GFR and changes in
tubular function in human renal diseases. Smith et
al [23] studied C1, TmG, TmD (tubular maximum of
Diodrast secretion) in hypertensive patients with
wide variations in GFR. There was a linear correla-
tion between GFR and proximal tubular function in
this group of patients. CJfl/TmG ratio was normal,
but CIfl/TmD was higher than normal. This was inter-
preted to mean that the impairment of Diodrast se-
cretion was disproportionately greater than the re-
duction in GFR in hypertension. TmPAH/GFR was
not different from the normal in 10 patients with es-
sential hypertension (whose GFR was decreased
slightly) and 5 patients with moderately reduced
GFR from glomerulonephritis [24]. Similar findings
were reported in 7 adults with polycystic kidney
disease whose GFR ranged from 5 to 93 mllmin [25].
In 15 patients who recovered from acute oliguric
renal failure, TmPAH/CIfl were not different from the
normal from 3 to 34 months alter the episode,
whereas GFR ranged from 35 to 106 mllmin [26]. As
to TmG/CIfl, there are even fewer clinical studies re-
ported. Seven adults with polycystic kidney disease
had mean TmG/CIfl of 2.31 (range, 1.86 to 2.60) [25].
TfflG/CIfl was higher than normal with chronic gb-
merulonephritis or chronic pyelonephritis [27]. The
nine patients with GFR ranging from 15 to 58 ml!
mm had a mean TmG/CJfl ratio of 3.99 (range, 2.63 to
6.51).
In lead poisoning, it can be seen clearly that the
reduction in TmG (Fig. 1) was disproportionately
greater than expected from the reduced GFR. On
the other hand, the changes in TmPAH in this group
of patients were not markedly deviated from the
normal (Fig. 2). These data indicate that in lead ex-
posure of as short as 3 months' duration where no
clinical evidence of renal involvement can be de-
tected by the routine clinical laboratory tests, the
tubular reabsorptive capacity for glucose is signifi-
cantly depressed but the secretory capacity for
PAH and hydrogen ion (Tm110) remain unchanged.
Lead did not affect urinary excretion of f32-micro-
globulin.
In summary, although routine clinical laboratory
tests do not suggest renal dysfunction, patients with
lead exposure as short as 3 months may have signif-
icantly reduced GFR (C1), markedly decreased glu-
cose reabsorptive capacity, normal bicarbonate
reabsorptive capacity, and normal PAH secretory
capacity. Routine clinical laboratory tests are in-
sensitive for the detection of renal effects of lead
exposure. Measurement of renal tubular reabsorp-
tive capacity for glucose appears to be a sensitive
method for the detection of subclinical lead nephro-
toxicity.
In contrast, unreported studies by us have failed
to demonstrate this disproportionate reduction in
TmG in one case of cadmium nephropathy (C1,,, 81
mL/min/l .73 m2) and one case of chronic exposure to
mercury vapor (C1,,, 44 mllmin!1 .73 m2), suggesting
a specific transport defect in the renal proximal tu-
bule in lead nephropathy. Both cadmium and mer-
cury exposures resulted in increased urinary f32-mi-
croglobulin excretion.
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